DOI: 10.1128/aac.47.5.1681-1688.2003. Surveillance for Antimicrobial Susceptibility among Clinical Isolates of <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i> from Hospitalized Patients in the United States, 1998 to 2001

Surveillance for Antimicrobial Susceptibility among Clinical Isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from Hospitalized Patients in the United States, 1998 to 2001

10.1128/aac.47.5.1681-1688.2003

Crossref journal-article

American Society for Microbiology

Antimicrobial Agents and Chemotherapy (235)

Abstract

ABSTRACT Pseudomonas aeruginosa and Acinetobacter baumannii are the most prevalent nonfermentative bacterial species isolated from clinical specimens of hospitalized patients. A surveillance study of 65 laboratories in the United States from 1998 to 2001 found >90% of isolates of P . aeruginosa from hospitalized patients to be susceptible to amikacin and piperacillin-tazobactam; 80 to 90% of isolates to be susceptible to cefepime, ceftazidime, imipenem, and meropenem; and 70 to 80% of isolates to be susceptible to ciprofloxacin, gentamicin, levofloxacin, and ticarcillin-clavulanate. From 1998 to 2001, decreases in antimicrobial susceptibility (percents) among non-intensive-care-unit (non-ICU) inpatients and ICU patients, respectively, were greatest for ciprofloxacin (6.1 and 6.5), levofloxacin (6.6 and 3.5), and ceftazidime (4.8 and 3.3). Combined 1998 to 2001 results for A . baumannii isolated from non-ICU inpatients and ICU patients, respectively, demonstrated that >90% of isolates tested were susceptible to imipenem (96.5 and 96.6%) and meropenem (91.6 and 91.7%); fewer isolates from both non-ICU inpatients and ICU patients were susceptible to amikacin and ticarcillin-clavulanate (70 to 80% susceptible); and <60% of isolates were susceptible to ceftazidime, ciprofloxacin, gentamicin, or levofloxacin. From 1998 to 2001, rates of multidrug resistance (resistance to at least three of the drugs ceftazidime, ciprofloxacin, gentamicin, and imipenem) showed small increases among P . aeruginosa strains isolated from non-ICU inpatients (5.5 to 7.0%) and ICU patients (7.4 to 9.1%). From 1998 to 2001, rates of multidrug resistance among A . baumannii strains isolated from non-ICU inpatients (27.6 to 32.5%) and ICU patients (11.6 to 24.2%) were higher and more variable than those observed for P . aeruginosa . Isolates concurrently susceptible, intermediate, or resistant to both imipenem and meropenem accounted for 89.8 and 91.2% of P . aeruginosa and A . baumannii isolates, respectively, studied from 1998 to 2001. In conclusion, for aminoglycosides and most β-lactams susceptibility rates for P . aeruginosa and A . baumannii were constant or decreased only marginally (≤3%) from 1998 to 2001. Greater decreases in susceptibility rates were, however, observed for fluoroquinolones and ceftazidime among P . aeruginosa isolates.

Bibliography

Karlowsky, J. A., Draghi, D. C., Jones, M. E., Thornsberry, C., Friedland, I. R., & Sahm, D. F. (2003). Surveillance for Antimicrobial Susceptibility among Clinical Isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from Hospitalized Patients in the United States, 1998 to 2001. Antimicrobial Agents and Chemotherapy, 47(5), 1681â1688.

Authors 6

James A. Karlowsky (first)
Deborah C. Draghi (additional)
Mark E. Jones (additional)
Clyde Thornsberry (additional)
Ian R. Friedland (additional)
Daniel F. Sahm (additional)

References 32 Referenced 235

10.1016/S0195-6701(98)90243-2
10.1128/JCM.38.9.3299-3305.2000
10.1128/AAC.44.6.1556-1561.2000
Bukholm, G., T. Tannaes, A. B. Kjelsberg, and N. Smith-Erichsen. 2002. An outbreak of multidrug-resistant Pseudomonas aeruginosa associated with increased risk of patient death in an intensive care unit. Infect. Control Hosp. Epidemiol.23:441-446. (10.1086/502082) / Infect. Control Hosp. Epidemiol. (2002)
10.1128/AAC.39.6.1211
10.1001/archinte.159.10.1127
Chen, H. Y., M. Yuan, I. B. Ibrahim-Elmagboul, and D. M. Livermore. 1995. National survey of susceptibility to antimicrobials amongst clinical isolates of Pseudomonas aeruginosa. J. Antimicrob. Chemother.35:521-534. (10.1093/jac/35.4.521) / J. Antimicrob. Chemother. (1995)
10.1086/598640
10.1093/clinids/23.3.538
10.1128/AAC.40.6.1412
10.1086/320183
10.1086/320186
10.1086/514760
Jones, R. N. 1999. Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia. Clin. Infect. Dis.29:495-502. (10.1086/598621) / Clin. Infect. Dis. (1999)
10.1016/S0732-8893(02)00390-5
10.1016/S0732-8893(97)00234-4
10.1016/S0924-8579(01)00466-6
Kiska D. L. and P. H. Gilligan. 1999. Pseudomonas p. 517-525. In P. R. Murray E. J. Baron M. A. Pfaller F. C. Tenover and R. H. Yolken (ed.) Manual of clinical microbiology 7th ed. ASM Press Washington D.C.
10.1001/archinte.162.13.1515
10.1093/jac/47.3.247
10.1086/313902
National Committee on Clinical Laboratory Standards. 2002. Performance standards for antimicrobial susceptibility testing; 11th informational supplement. Vol. 22 no. 1. M100-S12. National Committee for Clinical Laboratory Standards Wayne Pa.
10.1067/mic.2000.110544
Pfaller, M. A., and R. N. Jones. 1997. A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated worldwide. Diagn. Microbiol. Infect. Dis.28:157-163. (10.1016/S0732-8893(97)00065-5) / Diagn. Microbiol. Infect. Dis. (1997)
10.1016/S0732-8893(01)00319-4
10.1128/AAC.42.7.1762
Pollack M. 2000. Pseudomonas aeruginosa p. 2310-2335. In G. L. Mandell. J. E. Bennett and R. Dolin (ed.) Principles and practice of infectious diseases 5th ed. Churchill Livingstone Philadelphia Pa.
10.1128/AAC.45.1.267-274.2001
10.1086/520195
Schreckenberger P. C. and A. von Graevenitz. 1999. Acinetobacter Achromobacter Alcaligenes Moraxella Methylobacterium and other nonfermentative gram-negative rods p. 539-560. In P. R. Murray E. J. Baron M. A. Pfaller F. C. Tenover and R. H. Yolken (ed.) Manual of clinical microbiology 7th ed. ASM Press Washington D.C.
10.1093/jac/40.5.740
10.1128/jcm.32.11.2677-2681.1994

Dates

Type	When
Created	22 years, 4 months ago (April 22, 2003, 5:03 p.m.)
Deposited	3 years, 6 months ago (Feb. 21, 2022, 1:13 p.m.)
Indexed	1 month ago (Aug. 7, 2025, 4:54 p.m.)
Issued	22 years, 4 months ago (May 1, 2003)
Published	22 years, 4 months ago (May 1, 2003)
Published Print	22 years, 4 months ago (May 1, 2003)

Funders 0

None

BibTeX

@article{Karlowsky_2003, title={Surveillance for Antimicrobial Susceptibility among Clinical Isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from Hospitalized Patients in the United States, 1998 to 2001}, volume={47}, ISSN={1098-6596}, url={http://dx.doi.org/10.1128/aac.47.5.1681-1688.2003}, DOI={10.1128/aac.47.5.1681-1688.2003}, number={5}, journal={Antimicrobial Agents and Chemotherapy}, publisher={American Society for Microbiology}, author={Karlowsky, James A. and Draghi, Deborah C. and Jones, Mark E. and Thornsberry, Clyde and Friedland, Ian R. and Sahm, Daniel F.}, year={2003}, month=may, pages={1681–1688} }

JSON

{
  "indexed": {
    "date-parts": [
      [
        2025,
        8,
        7
      ]
    ],
    "date-time": "2025-08-07T20:54:11Z",
    "timestamp": 1754600051083
  },
  "reference-count": 32,
  "publisher": "American Society for Microbiology",
  "issue": "5",
  "license": [
    {
      "start": {
        "date-parts": [
          [
            2003,
            5,
            1
          ]
        ],
        "date-time": "2003-05-01T00:00:00Z",
        "timestamp": 1051747200000
      },
      "content-version": "tdm",
      "delay-in-days": 0,
      "URL": "https://journals.asm.org/non-commercial-tdm-license"
    }
  ],
  "content-domain": {
    "domain": [
      "journals.asm.org"
    ],
    "crossmark-restriction": true
  },
  "published-print": {
    "date-parts": [
      [
        2003,
        5
      ]
    ]
  },
  "abstract": "<jats:title>ABSTRACT</jats:title>\n          <jats:p>\n            <jats:italic>Pseudomonas aeruginosa</jats:italic>\n            and\n            <jats:italic>Acinetobacter baumannii</jats:italic>\n            are the most prevalent nonfermentative bacterial species isolated from clinical specimens of hospitalized patients. A surveillance study of 65 laboratories in the United States from 1998 to 2001 found &gt;90% of isolates of\n            <jats:italic>P</jats:italic>\n            .\n            <jats:italic>aeruginosa</jats:italic>\n            from hospitalized patients to be susceptible to amikacin and piperacillin-tazobactam; 80 to 90% of isolates to be susceptible to cefepime, ceftazidime, imipenem, and meropenem; and 70 to 80% of isolates to be susceptible to ciprofloxacin, gentamicin, levofloxacin, and ticarcillin-clavulanate. From 1998 to 2001, decreases in antimicrobial susceptibility (percents) among non-intensive-care-unit (non-ICU) inpatients and ICU patients, respectively, were greatest for ciprofloxacin (6.1 and 6.5), levofloxacin (6.6 and 3.5), and ceftazidime (4.8 and 3.3). Combined 1998 to 2001 results for\n            <jats:italic>A</jats:italic>\n            .\n            <jats:italic>baumannii</jats:italic>\n            isolated from non-ICU inpatients and ICU patients, respectively, demonstrated that &gt;90% of isolates tested were susceptible to imipenem (96.5 and 96.6%) and meropenem (91.6 and 91.7%); fewer isolates from both non-ICU inpatients and ICU patients were susceptible to amikacin and ticarcillin-clavulanate (70 to 80% susceptible); and &lt;60% of isolates were susceptible to ceftazidime, ciprofloxacin, gentamicin, or levofloxacin. From 1998 to 2001, rates of multidrug resistance (resistance to at least three of the drugs ceftazidime, ciprofloxacin, gentamicin, and imipenem) showed small increases among\n            <jats:italic>P</jats:italic>\n            .\n            <jats:italic>aeruginosa</jats:italic>\n            strains isolated from non-ICU inpatients (5.5 to 7.0%) and ICU patients (7.4 to 9.1%). From 1998 to 2001, rates of multidrug resistance among\n            <jats:italic>A</jats:italic>\n            .\n            <jats:italic>baumannii</jats:italic>\n            strains isolated from non-ICU inpatients (27.6 to 32.5%) and ICU patients (11.6 to 24.2%) were higher and more variable than those observed for\n            <jats:italic>P</jats:italic>\n            .\n            <jats:italic>aeruginosa</jats:italic>\n            . Isolates concurrently susceptible, intermediate, or resistant to both imipenem and meropenem accounted for 89.8 and 91.2% of\n            <jats:italic>P</jats:italic>\n            .\n            <jats:italic>aeruginosa</jats:italic>\n            and\n            <jats:italic>A</jats:italic>\n            .\n            <jats:italic>baumannii</jats:italic>\n            isolates, respectively, studied from 1998 to 2001. In conclusion, for aminoglycosides and most \u03b2-lactams susceptibility rates for\n            <jats:italic>P</jats:italic>\n            .\n            <jats:italic>aeruginosa</jats:italic>\n            and\n            <jats:italic>A</jats:italic>\n            .\n            <jats:italic>baumannii</jats:italic>\n            were constant or decreased only marginally (\u22643%) from 1998 to 2001. Greater decreases in susceptibility rates were, however, observed for fluoroquinolones and ceftazidime among\n            <jats:italic>P</jats:italic>\n            .\n            <jats:italic>aeruginosa</jats:italic>\n            isolates.\n          </jats:p>",
  "DOI": "10.1128/aac.47.5.1681-1688.2003",
  "type": "journal-article",
  "created": {
    "date-parts": [
      [
        2003,
        4,
        22
      ]
    ],
    "date-time": "2003-04-22T21:03:23Z",
    "timestamp": 1051045403000
  },
  "page": "1681-1688",
  "update-policy": "http://dx.doi.org/10.1128/asmj-crossmark-policy-page",
  "source": "Crossref",
  "is-referenced-by-count": 235,
  "title": "Surveillance for Antimicrobial Susceptibility among Clinical Isolates of\n            <i>Pseudomonas aeruginosa</i>\n            and\n            <i>Acinetobacter baumannii</i>\n            from Hospitalized Patients in the United States, 1998 to 2001",
  "prefix": "10.1128",
  "volume": "47",
  "author": [
    {
      "given": "James A.",
      "family": "Karlowsky",
      "sequence": "first",
      "affiliation": [
        {
          "name": "Focus Technologies, Herndon, Virginia 20171"
        }
      ]
    },
    {
      "given": "Deborah C.",
      "family": "Draghi",
      "sequence": "additional",
      "affiliation": [
        {
          "name": "Focus Technologies, Herndon, Virginia 20171"
        }
      ]
    },
    {
      "given": "Mark E.",
      "family": "Jones",
      "sequence": "additional",
      "affiliation": [
        {
          "name": "Focus Technologies, 1217 KP Hilversum, The Netherlands"
        }
      ]
    },
    {
      "given": "Clyde",
      "family": "Thornsberry",
      "sequence": "additional",
      "affiliation": [
        {
          "name": "Focus Technologies, Franklin, Tennessee 37064"
        }
      ]
    },
    {
      "given": "Ian R.",
      "family": "Friedland",
      "sequence": "additional",
      "affiliation": [
        {
          "name": "Merck Research Laboratories, West Point, Pennsylvania 19486"
        }
      ]
    },
    {
      "given": "Daniel F.",
      "family": "Sahm",
      "sequence": "additional",
      "affiliation": [
        {
          "name": "Focus Technologies, Herndon, Virginia 20171"
        }
      ]
    }
  ],
  "member": "235",
  "reference": [
    {
      "key": "e_1_3_2_2_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1016/S0195-6701(98)90243-2"
    },
    {
      "key": "e_1_3_2_3_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1128/JCM.38.9.3299-3305.2000"
    },
    {
      "key": "e_1_3_2_4_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1128/AAC.44.6.1556-1561.2000"
    },
    {
      "key": "e_1_3_2_5_2",
      "doi-asserted-by": "crossref",
      "first-page": "441",
      "DOI": "10.1086/502082",
      "volume": "23",
      "year": "2002",
      "unstructured": "Bukholm, G., T. Tannaes, A. B. Kjelsberg, and N. Smith-Erichsen. 2002. An outbreak of multidrug-resistant Pseudomonas aeruginosa associated with increased risk of patient death in an intensive care unit. Infect. Control Hosp. Epidemiol.23:441-446.",
      "journal-title": "Infect. Control Hosp. Epidemiol."
    },
    {
      "key": "e_1_3_2_6_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1128/AAC.39.6.1211"
    },
    {
      "key": "e_1_3_2_7_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1001/archinte.159.10.1127"
    },
    {
      "key": "e_1_3_2_8_2",
      "doi-asserted-by": "crossref",
      "first-page": "521",
      "DOI": "10.1093/jac/35.4.521",
      "volume": "35",
      "year": "1995",
      "unstructured": "Chen, H. Y., M. Yuan, I. B. Ibrahim-Elmagboul, and D. M. Livermore. 1995. National survey of susceptibility to antimicrobials amongst clinical isolates of Pseudomonas aeruginosa. J. Antimicrob. Chemother.35:521-534.",
      "journal-title": "J. Antimicrob. Chemother."
    },
    {
      "key": "e_1_3_2_9_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1086/598640"
    },
    {
      "key": "e_1_3_2_10_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1093/clinids/23.3.538"
    },
    {
      "key": "e_1_3_2_11_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1128/AAC.40.6.1412"
    },
    {
      "key": "e_1_3_2_12_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1086/320183"
    },
    {
      "key": "e_1_3_2_13_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1086/320186"
    },
    {
      "key": "e_1_3_2_14_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1086/514760"
    },
    {
      "key": "e_1_3_2_15_2",
      "doi-asserted-by": "crossref",
      "first-page": "495",
      "DOI": "10.1086/598621",
      "volume": "29",
      "year": "1999",
      "unstructured": "Jones, R. N. 1999. Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia. Clin. Infect. Dis.29:495-502.",
      "journal-title": "Clin. Infect. Dis."
    },
    {
      "key": "e_1_3_2_16_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1016/S0732-8893(02)00390-5"
    },
    {
      "key": "e_1_3_2_17_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1016/S0732-8893(97)00234-4"
    },
    {
      "key": "e_1_3_2_18_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1016/S0924-8579(01)00466-6"
    },
    {
      "key": "e_1_3_2_19_2",
      "unstructured": "Kiska D. L. and P. H. Gilligan. 1999. Pseudomonas p. 517-525. In P. R. Murray E. J. Baron M. A. Pfaller F. C. Tenover and R. H. Yolken (ed.) Manual of clinical microbiology 7th ed. ASM Press Washington D.C."
    },
    {
      "key": "e_1_3_2_20_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1001/archinte.162.13.1515"
    },
    {
      "key": "e_1_3_2_21_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1093/jac/47.3.247"
    },
    {
      "key": "e_1_3_2_22_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1086/313902"
    },
    {
      "key": "e_1_3_2_23_2",
      "unstructured": "National Committee on Clinical Laboratory Standards. 2002. Performance standards for antimicrobial susceptibility testing; 11th informational supplement. Vol. 22 no. 1. M100-S12. National Committee for Clinical Laboratory Standards Wayne Pa."
    },
    {
      "key": "e_1_3_2_24_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1067/mic.2000.110544"
    },
    {
      "key": "e_1_3_2_25_2",
      "doi-asserted-by": "crossref",
      "first-page": "157",
      "DOI": "10.1016/S0732-8893(97)00065-5",
      "volume": "28",
      "year": "1997",
      "unstructured": "Pfaller, M. A., and R. N. Jones. 1997. A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated worldwide. Diagn. Microbiol. Infect. Dis.28:157-163.",
      "journal-title": "Diagn. Microbiol. Infect. Dis."
    },
    {
      "key": "e_1_3_2_26_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1016/S0732-8893(01)00319-4"
    },
    {
      "key": "e_1_3_2_27_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1128/AAC.42.7.1762"
    },
    {
      "key": "e_1_3_2_28_2",
      "unstructured": "Pollack M. 2000. Pseudomonas aeruginosa p. 2310-2335. In G. L. Mandell. J. E. Bennett and R. Dolin (ed.) Principles and practice of infectious diseases 5th ed. Churchill Livingstone Philadelphia Pa."
    },
    {
      "key": "e_1_3_2_29_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1128/AAC.45.1.267-274.2001"
    },
    {
      "key": "e_1_3_2_30_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1086/520195"
    },
    {
      "key": "e_1_3_2_31_2",
      "unstructured": "Schreckenberger P. C. and A. von Graevenitz. 1999. Acinetobacter Achromobacter Alcaligenes Moraxella Methylobacterium and other nonfermentative gram-negative rods p. 539-560. In P. R. Murray E. J. Baron M. A. Pfaller F. C. Tenover and R. H. Yolken (ed.) Manual of clinical microbiology 7th ed. ASM Press Washington D.C."
    },
    {
      "key": "e_1_3_2_32_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1093/jac/40.5.740"
    },
    {
      "key": "e_1_3_2_33_2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1128/jcm.32.11.2677-2681.1994"
    }
  ],
  "container-title": "Antimicrobial Agents and Chemotherapy",
  "original-title": [],
  "language": "en",
  "link": [
    {
      "URL": "https://journals.asm.org/doi/pdf/10.1128/AAC.47.5.1681-1688.2003",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://journals.asm.org/doi/pdf/10.1128/AAC.47.5.1681-1688.2003",
      "content-type": "unspecified",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "deposited": {
    "date-parts": [
      [
        2022,
        2,
        21
      ]
    ],
    "date-time": "2022-02-21T18:13:34Z",
    "timestamp": 1645467214000
  },
  "score": 1,
  "resource": {
    "primary": {
      "URL": "https://journals.asm.org/doi/10.1128/AAC.47.5.1681-1688.2003"
    }
  },
  "subtitle": [],
  "short-title": [],
  "issued": {
    "date-parts": [
      [
        2003,
        5
      ]
    ]
  },
  "references-count": 32,
  "journal-issue": {
    "issue": "5",
    "published-print": {
      "date-parts": [
        [
          2003,
          5
        ]
      ]
    }
  },
  "alternative-id": [
    "10.1128/AAC.47.5.1681-1688.2003"
  ],
  "URL": "http://dx.doi.org/10.1128/AAC.47.5.1681-1688.2003",
  "relation": {},
  "ISSN": [
    "0066-4804",
    "1098-6596"
  ],
  "subject": [],
  "container-title-short": "Antimicrob Agents Chemother",
  "published": {
    "date-parts": [
      [
        2003,
        5
      ]
    ]
  },
  "assertion": [
    {
      "value": "2002-10-22",
      "order": 0,
      "name": "received",
      "label": "Received",
      "group": {
        "name": "publication_history",
        "label": "Publication History"
      }
    },
    {
      "value": "2003-02-14",
      "order": 1,
      "name": "accepted",
      "label": "Accepted",
      "group": {
        "name": "publication_history",
        "label": "Publication History"
      }
    },
    {
      "value": "2003-05-01",
      "order": 2,
      "name": "published",
      "label": "Published",
      "group": {
        "name": "publication_history",
        "label": "Publication History"
      }
    }
  ]
}